News and Events

Dr. Zhu Xixu, Director of the Department of Radiation Oncology at NGH. “Electron IORT has demonstrated significant benefits in the treatment of locally advanced and recurrent cancers as well early stage breast cancer. The Mobetron expands our ability to treat these cancers and ensures our patients have access to the best possible treatment options to aid their fight against cancer.”

IntraOp Medical is proudly sponsoring the School of Oncoplastic Surgery Dallas January 22-24, 2016 Didactic lectures Full day cadaver lab Evening sculpture lab One on one with expert faculty Live models for surgical markings Enhance and learn new surgical skills Networking with faculty & colleagues Featuring new technologies in the lab Learn about coding for … Continued

The GEC-ESTRO Phase III trial validates the oncologic concept of APBI. The results of the GEC-ESTRO phase III trial comparing APBI versus WBI are significant and potentially practice changing in that they indicate for the first time (in a large, well-designed, contemporary phase III trial with adequate follow-up) that the scientific concept of treating only the lumpectomy cavity (plus a proper margin) is just as effective and safe as treating the whole breast in selected patients with early stage breast cancer.

For decades, electron IORT has been used for locally advanced and recurrent cancers, achieving excellent clinical results in both local control and survival, especially in indications where it is often difficult to obtain clear surgical margins such as pancreatic cancer, colorectal cancers, head and neck cancers, GYN cancers, and sarcomas. The National Comprehensive Cancer Network (NCCN)http://www.nccn.org has recommended IORT with electrons as the treatment of choice for locally advanced and recurrent rectal cancer.

IORT – Smaller, mobile delivery systems and new clinical evidence are driving this innovative form of radiation therapy, which can significantly reduce the associated burdens of treatment for patients.